Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-00489791. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-00489791 SCHEMBL29379715 | 1.00 | PDE5A (1.00) | PDE5AKCNH2 | |
| SCHEMBL332278 | 0.94 | PDE5A (0.89) | PDE5AKCNH2 | |
| SCHEMBL332144 | 0.92 | PDE5A (0.85) | PDE5AKCNH2 | |
| SCHEMBL332775 | 0.92 | PDE5A (0.85) | PDE5AKCNH2 | |
| SCHEMBL331777 | 0.92 | PDE5A (0.85) | PDE5AKCNH2 | |
| SCHEMBL331644 | 0.92 | PDE5A (0.85) | PDE5AKCNH2 | |
| SCHEMBL331423 | 0.91 | PDE5A (0.83) | PDE5AKCNH2 | |
| SCHEMBL2878701 | 0.89 | PDE5A (0.80) | PDE5AKCNH2 | |
| SCHEMBL8297001 | 0.89 | PDE5A (0.80) | PDE5AKCNH2 | |
| SCHEMBL332820 | 0.88 | PDE5A (0.79) | PDE5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| WO-2023018795-A1 | NEP INHIBITORS FOR THE TREATMENT OF LAMINITIS | CURTAILS LLC (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022265984-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-3185903-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | Fundación para la Investigación Médica Aplicada (ES) | 2017-07-05 | — | — | EP | claimed |
| US-20160136170-A1 | USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY | PFIZER INC. (US) | 2016-05-19 | — | — | US | claimed |
| WO-2016030345-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-03-03 | — | — | WO | claimed |
| US-20150274735-A1 | USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY | PFIZER INC. (US) | 2015-10-01 | — | — | US | claimed |
| EP-2911672-A1 | USE OF A TETRASUBSTITUTED PYRAZOLO[4,3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY | Pfizer Inc. (US) | 2015-09-02 | — | — | EP | claimed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | claimed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | claimed |
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PFIZER INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | claimed |
| WO-2009050554-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 2009-04-23 | — | — | WO | claimed |
| US-20080293746-A1 | COMBINATIONS COMPRISING PREGABALIN | PFIZER, INC. (US) | 2008-11-27 | — | — | US | claimed |
| US-20080194591-A1 | Phosphodiesterase inhibitor | PFIZER INC. | 2008-08-14 | — | — | US | claimed |
| EP-1881985-A2 | ANHYDROUS CRYSTALLINE FORMS OF N-Ý1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-YL-AMINO)-1H-PYRAZOLO[4,3-D]PYRIMIDINE-3-CARBONYL¨METHANESULFONAMIDE | Pfizer, Inc. (US) | 2008-01-30 | — | — | EP | claimed |
| WO-2006120552-A2 | ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE | PFIZER INC. (US) | 2006-11-16 | — | — | WO | claimed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | PDE5A 545/4885KCNH2 3699/4885 |
| US-20080194591-A1 | Phosphodiesterase inhibitor | PDE5A, PDE3B, PDE3A | PDE5A 1/4885KCNH2 485/4885 |
| US-20080293746-A1 | COMBINATIONS COMPRISING PREGABALIN | GABRB2, GABRG3, GABRB3 | PDE5A 1090/4885KCNH2 263/4885 |
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | PDE5A 103/4885KCNH2 2253/4885 |
| US-20160136170-A1 | USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY | SLC5A1, SLC5A2, GLS | PDE5A 459/4885KCNH2 1874/4885 |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | MME, REN, ACE | PDE5A 281/4885KCNH2 2472/4885 |
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PDE4A, PDE12, PDE4B | PDE5A 4/4885KCNH2 2609/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | PDE5A 103/4885KCNH2 2253/4885 |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | MME, REN, ACE | PDE5A 100/4885KCNH2 2273/4885 |
| US-20150274735-A1 | USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY | SLC5A1, GLS, SLC5A2 | PDE5A 338/4885KCNH2 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.